Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL308738 | 0.85 | ALDH1A1 (0.66) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL10622511 | 0.84 | ALDH1A1 (0.63) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL28140827 | 0.84 | ALDH1A1 (0.44) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL19026667 | 0.83 | ALDH1A1 (0.58) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL7363268 | 0.81 | ALDH1A1 (0.66) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL2030599 | 0.81 | ALDH1A1 (0.70) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL340272 | 0.81 | ALDH1A1 (0.70) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL8516064 | 0.81 | ALDH1A1 (0.59) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL14817542 | 0.81 | ALDH1A1 (0.59) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL4874004 | 0.80 | ALDH1A1 (0.42) | ALDH1A1GLATSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714020-B2 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2010-05-11 | — | — | US | claimed |
| JP-2009519467-A | — | — | 2009-05-14 | — | — | JP | claimed |
| EP-1990639-A1 | System and method for real-time diagnosis, treatment, and therapeutic drug monitoring | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-11-12 | — | — | EP | claimed |
| EP-1960775-A2 | SYSTEM AND METHOD FOR MONITORING HEALTH USING EXHALED BREATH | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-08-27 | — | — | EP | claimed |
| US-20070258894-A1 | System and Method for Real-Time Diagnosis, Treatment, and Therapeutic Drug Monitoring | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2007-11-08 | — | — | US | claimed |
| JP-2007525670-A | — | — | 2007-09-06 | — | — | JP | claimed |
| WO-2007089328-A2 | SYSTEM AND METHOD FOR MONITORING HEALTH USING EXHALED BREATH | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2007-08-09 | — | — | WO | claimed |
| US-20070167853-A1 | System and method for monitoring health using exhaled breath | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2007-07-19 | — | — | US | claimed |
| US-20060251649-A1 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-09 | — | — | US | claimed |
| EP-1718971-A2 | SYSTEM AND METHOD FOR REAL-TIME DIAGNOSIS, TREATMENT, AND THERAPEUTIC DRUG MONITORING | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2006-11-08 | — | — | EP | claimed |
| WO-2005098429-A2 | SYSTEM AND METHOD FOR REAL-TIME DIAGNOSIS, TREATMENT, AND THERAPEUTIC DRUG MONITORING | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2005-10-20 | — | — | WO | claimed |
| US-20050233459-A1 | Marker detection method and apparatus to monitor drug compliance | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2005-10-20 | — | — | US | claimed |
| US-20050054942-A1 | System and method for therapeutic drug monitoring | UNIVERSITY OF FLORIDA | 2005-03-10 | — | — | US | claimed |
| US-20250144013-A1 | Mycophenolate Oral Suspension | LIQMEDS WORLDWIDE LTD (GB) | 2025-05-08 | — | — | US | disclosed |
| US-20250070260-A1 | SLOT ELECTRODE STACK AND ELECTROCHEMICAL CELLS AND BATTERIES CONTAINING A SLOT ELECTRODE STACK | SEED INTELLECTUAL PROPERTY LAW GROUP LLP | 2025-02-27 | — | — | US | disclosed |
| US-12226526-B2 | Mycophenolate oral suspension | LIQMEDS WORLDWIDE LIMITED (GB) | 2025-02-18 | — | — | US | disclosed |
| WO-2004052350-A2 | METHOD OF TREATING MOVEMENT DISORDERS USING BARBITURIC ACID DERIVATIVES | TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2004-06-24 | — | — | WO | disclosed |
| EP-0511003-B1 | Superactive GRF analogs | LILLY CO ELI (US) | 1999-03-24 | — | — | EP | disclosed |
| EP-0511003-A1 | Superactive GRF analogs | ELI LILLY AND COMPANY (US) | 1992-10-28 | — | — | EP | disclosed |
| WO-1989009209-A1 | PIPERIDINE RING MODIFIED PHENCYCLIDINE ANALOGS AS ANTICONVULSANTS | MARION LABORATORIES, INC. (US) | 1989-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060251649-A1 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | GRM2, GRIN2C, GRIN2A | ALDH1A1 2555/4885GLA 1206/4885TSHR 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.